New Delhi: The pharmaceutical company will introduce anti-viral anti-viral drug remadecivir for the treatment of hetero covid-19. The company said on Sunday that it has received the permission of the Controller General of Indian Medicine (DCGI) for this.
Hetero said in the statement that the company had received permission from DCGI to manufacture and market Remedesvir. The generic version of Remdesvir will be sold in India under the brand name ‘Koviphor’. The statement said that DCGI has allowed this drug to treat cases of suspected or confirmed Covid-19 in adults and children or those hospitalized due to its infection.
The company said that covid-19 cases in India are increasing rapidly. In such a situation, allowing Kovifor can prove to be dice-reversing, as its clinical results have been quite positive. “We will ensure that this product is available to patients across the country soon,” said B Partha Saradhi Reddy, chairman of the Hetero Group of Companies, adding that the company would ensure sufficient stock to meet the current requirement. This drug will be available as a 100mg vial (injection). The product is being launched in the Indian market under a licensing agreement with Gilead Sciences Inc.
